Literature DB >> 10920477

Factors prior to dry period associated with high and low levels of cow milk somatic cell counts in next lactation.

O Osterås1, V L Edge.   

Abstract

Data from a randomized controlled field study of selective dry cow therapy were used in which 686 cows had been allocated to 2 control groups (sampling only or placebo) or 2 therapy groups. Possible factors from previous lactation were assessed in determining their association with the probability of 'failure', designated as a cow milk somatic cell count (CMSCC) of greater than 399,000 per ml in geometric mean of several measurements during subsequent lactation. Success cows were those with a CMSCC of less than 200,000 per ml. For our analyses, this targeted 187 success cows and 186 failure cows. Therapy was given as a total dose of 400,000 IU penicillin and 100 mg neomycin per infected quarter as dry cow preparation once, or as a lactation formula with a total dose of 1.2 million IU penicillin and 1,200 mg dihydrostreptomycin per infected quarter during a 1-week period. Significant factors in the predictive model for success included therapy, low level of CMSCC (geometric mean of the 3 last tests) in previous lactation, low level of CMSCC (weighted by daily milk yield mean) in the herd, young cows, and not having had a case of treatment for chronic clinical mastitis. Additional information on the probability of failure in treated and untreated cows can be predicted by number of quarters infected with Staphylococcus aureus approximately 1.5 months before drying off. The models derived are considered for use as tools in selective treatment and culling decisions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10920477      PMCID: PMC7996417     

Source DB:  PubMed          Journal:  Acta Vet Scand        ISSN: 0044-605X            Impact factor:   1.695


  8 in total

1.  Coding ordinal independent variables in multiple regression analyses.

Authors:  S D Walter; A R Feinstein; C K Wells
Journal:  Am J Epidemiol       Date:  1987-02       Impact factor: 4.897

2.  [Nordic recommendations for mastitis examinations of gland samples].

Authors:  O Klastrup; S Madsen
Journal:  Nord Vet Med       Date:  1974-03

3.  Determinants of success or failure in the elimination of major mastitis pathogens in selective dry cow therapy.

Authors:  O Osterås; V L Edge; S W Martin
Journal:  J Dairy Sci       Date:  1999-06       Impact factor: 4.034

4.  Possible risk factors associated with penicillin-resistant strains of Staphylococcus aureus from bovine subclinical mastitis in early lactation.

Authors:  O Osterås; S W Martin; V L Edge
Journal:  J Dairy Sci       Date:  1999-05       Impact factor: 4.034

5.  Effects of selective dry-cow therapy on culling rate, clinical mastitis, milk yield and cow somatic cell count. A randomized clinical field study in cows.

Authors:  O Osterås; L Sandvik
Journal:  Zentralbl Veterinarmed B       Date:  1996-11

6.  Assessment of strategy in selective dry cow therapy for mastitis control.

Authors:  O Osterås; L Sandvik; J Aursjø; G G Gjul; A Jørstad
Journal:  Zentralbl Veterinarmed B       Date:  1991-09

7.  Factors associated with bacteriological cure after dry cow treatment of subclinical staphylococcal mastitis with antibiotics.

Authors:  J Sol; O C Sampimon; J J Snoep; Y H Schukken
Journal:  J Dairy Sci       Date:  1994-01       Impact factor: 4.034

8.  Effect of dry-cow therapy on subclinical mastitis--an evaluation of long-acting and short-acting intramammaria.

Authors:  O Osterås; J Aursjø; G G Gjul; A Jørstad
Journal:  Zentralbl Veterinarmed B       Date:  1994-10
  8 in total
  2 in total

1.  Norwegian mastitis control programme.

Authors:  O Osterås; L Sølverød
Journal:  Ir Vet J       Date:  2009-04-01       Impact factor: 2.146

2.  Cow, farm, and herd management factors in the dry period associated with raised somatic cell counts in early lactation.

Authors:  M J Green; A J Bradley; G F Medley; W J Browne
Journal:  J Dairy Sci       Date:  2008-04       Impact factor: 4.034

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.